Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- MHLW to Report Two Remicade Biosimilars to PAFSC’s Second Committee on Drugs on May 26
May 15, 2014
- MHLW Sends FPMAJ Details of New Point-Based Calculations for New Drug Pricing
May 14, 2014
- PIC/S to Discuss Japan’s Accession at Upcoming Meeting in Rome; MHLW Anticipates Formal Approval
May 14, 2014
- PMDA Raises Caution about Concomitant Use of ACE Inhibitors and ARBs
May 13, 2014
- Pilot Program for Compassionate Access System Gets Underway with Sanofi’s Cabazitaxel
May 7, 2014
- Joint Panel of Health, Science Ministries Wraps Up Talks on Ethics Code for Epidemiological, Clinical Research
May 2, 2014
- Topical Ketoprofen Contraindicated in Later Pregnancy: MHLW Safety Information
May 2, 2014
- Point-Based Calculations for Premiums Will Improve Predictability, Says Creator
May 1, 2014
- PAFSC’s Second Committee Backs Approval of Janssen, Sanofi Prostate Cancer Drugs
May 1, 2014
- PAFSC’s First Committee Recommends Approval for SGLT-2 Inhibitor Canaglu
April 30, 2014
- Kitasato Daiichi to Carry on with Delayed Quota in Flu Vaccine Project, but Slapped with Delinquency Charges
April 30, 2014
- Kaketsuken, Takeda Picked for Flu Vaccine Project to Fill BIKEN Quota
April 30, 2014
- MHLW Issues Notification Calling for Revision of Package Insert for Sanofi’s Benambax
April 30, 2014
- MHLW Bureaucrats Think Chuikyo Will Spurn Annual Drug Price Revisions, Again
April 28, 2014
- MHLW Should Present Its Own Proposal to Design Envisioned Mixed Care System: Panel Chair
April 28, 2014
- PMDA’s Preliminary Meetings, Face-to-Face Counseling Rise in FY2013
April 28, 2014
- Chuikyo Healthcare Provider Rep Vexed by Health Minister Proposal on Use of Drug Cost-Effective Assessment
April 25, 2014
- JMA Veep Nakagawa Fumes at Industry, Says “Application Lag” Elicited New Mixed Care Proposal
April 25, 2014
- Chuikyo Subcommittee OKs Point-Based Premium Calculation Method, Adoption Scheduled in May
April 24, 2014
- LDP Study Group to Call for Expansion of R&D Tax Credit System, Oppose Annual NHI Price Cuts
April 24, 2014
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…